CTOs on the Move

Arisaph Pharmaceuticals

www.arisaph.com

 
Arisaph Pharmaceuticals is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.arisaph.com
  • 100 High St Ste 1202
    Boston, MA USA 02110
  • Phone: 617.986.4500

Executives

Name Title Contact Details

Similar Companies

Walter Payton Cancer Fund

Walter Payton Cancer Fund is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Parexel

PAREXEL International Corporation is the world`s leading innovator of biopharmaceutical services. We simplify our clients` journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world.

AOBiome

AOBiome LLC is developing first-in-class topical biologics for the treatment of inflammatory skin conditions. We have developed extensive scientific and manufacturing expertise on the use of beneficial ammonia-oxidizing bacteria (AOB). AOB are naturally occurring bacteria that metabolize the ammonia found in sweat, creating both nitrite and nitric oxide, with both anti-inflammatory and anti-infective properties. The therapeutic potential of nitrite and nitric oxide are widely recognized, although as yet, largely unrealized as delivery, let alone targeted delivery is extremely difficult. The company`s proprietary AOB offers the potential of a first-in-class natural delivery system for nitrite and nitric oxide.

Greenstone Biosciences

Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform to accelerate drug discovery.

Aptevo Therapeutics

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIRâ„¢ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients.